drugset / Trial / NCT02750995
Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this phase I study is to investigate the combination of hypomethylating agents with experimental peptide vaccination against four selected tumor antigens, known to be upregulated in response to hypomethylating agents, in patients with high risk myelodysplastic syndrome and acute myeloid leukemia.
Timeline
- Start
- 2016-04
- Primary completion
- 2018-01-02
- Completion
- 2019-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NPMW-peptide vaccine | Vaccine | 0.5 ml | Other |
| Background | Azacitidine | Other / unclassified | 100 mg/m2 | — |